Crenigacestat clinical trials
Also written LY3039478.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses crenigacestat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2016 (4)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 4 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Eli Lilly and Company (6) · GlaxoSmithKline (1) · Fred Hutchinson Cancer Center (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses crenigacestat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of LY3039478 in Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01695005Written as LY3039478
- A Study of LY3039478 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02659865Written as LY3039478 Capsule Formulation (Formulation 3)
- A Study of LY3039478 in Japanese Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02836600Written as LY3039478
- A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02917733Written as LY3039478
- Study of LY3039478 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02906618Written as LY3039478
- BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple MyelomaTerminatedPhase 1Fred Hutchinson Cancer CenterNCT03502577Written as Gamma-Secretase Inhibitor LY3039478
- A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBLCompletedPhase 1/2Eli Lilly and CompanyNCT02518113Written as LY3039478
- Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy VolunteersCompletedPhase 1GlaxoSmithKlineNCT00711776Written as New formulation
Given beside what is tested · 3 — crenigacestat is usual care or a partner of the new treatment
- Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple MyelomaTerminatedPhase 1CelgeneNCT04855136Written as BMS-986405
- A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsTerminatedPhase 1Eli Lilly and CompanyNCT02784795Written as LY3039478
- A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedPhase 1CelgeneNCT04036461Written as BMS-986405
Codes
What other systems call crenigacestat · ClinicalTrials.gg INT001210
- MeSH (NLM) C000654634crenigacestatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 923X28214SCRENIGACESTATConfirmed FDA, NLM
- NCI Thesaurus C171871CrenigacestatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654634 | crenigacestat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 923X28214S | CRENIGACESTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C171871 | Crenigacestat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.